Fasting insulin 12 µIU/mL — already insulin resistant?
A fasting insulin of 12 µIU/mL is above the optimal threshold most contemporary metabolic research uses. While conventional reference ranges typically extend to 25 µIU/mL, longitudinal studies tracking metabolic disease incidence identify ~8 µIU/mL as the upper bound of true metabolic health. A reading of 12 indicates compensated insulin resistance — your pancreas is over-secreting to keep glucose normal, and this compensation typically precedes overt prediabetes by 5–10 years. Most GP panels do not include fasting insulin, which is why this pattern frequently goes undetected.
Reference ranges
| Optimal (research literature) | < 8 µIU/mL |
| Borderline | 8 – 12 µIU/mL |
| Compensated insulin resistance | 12 – 25 µIU/mL |
| Severe | > 25 µIU/mL |
What this marker measures
Insulin is the master anabolic hormone, secreted by pancreatic beta cells in response to elevated blood glucose. After a 12-hour overnight fast, glucose should be stable and insulin demand low — a healthy fasting insulin reflects insulin-sensitive tissues. As muscle, liver, and adipose tissue become resistant, the pancreas compensates by secreting more insulin even at fasting glucose levels. This compensation keeps glucose in range for years before HbA1c rises, but the chronically elevated insulin itself drives downstream effects: visceral adiposity, hepatic VLDL production, hypertension, and atherogenesis.
Why might it be elevated?
- ·Visceral adiposity — strongest single predictor
- ·High-frequency carbohydrate intake (snacking pattern)
- ·Sedentary lifestyle reducing GLUT4 translocation in muscle
- ·Sleep deprivation (one week of <6h sleep can raise fasting insulin)
- ·Chronic cortisol elevation
- ·PCOS in women
- ·Sub-clinical hypothyroidism
Why might it be low?
- ·Athletic training, particularly fasted resistance training
- ·Prolonged fasting
- ·Late-stage type 2 diabetes (beta-cell exhaustion — usually with high glucose)
- ·Type 1 diabetes
Compounds whose research literature has investigated this area
These are research-grade compounds in our catalogue whose published study literature touches the same biology. Listed for research context — not as recommendations for self-administration.
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue — pre-reconstituted for researchers running extended protocols.
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked with GLP-1 receptor agonists in preclinical research.
MOTS-c is a 16-residue peptide encoded in the mitochondrial 12S rRNA region. Described by the Cohen lab in 2015 — studied in metabolic and exercise biology.
FAQ
Should I worry about fasting insulin 12 if my glucose and HbA1c are normal?+
Research literature strongly suggests yes — chronically elevated fasting insulin is associated with cardiovascular events, hepatic steatosis, and incident type 2 diabetes years before glucose markers shift. The WHO and ADA criteria don't catch this phase.
Calculate HOMA-IR from this+
HOMA-IR = (fasting glucose mmol/L × fasting insulin µIU/mL) / 22.5. With a fasting glucose of, say, 5.2 mmol/L, HOMA-IR = (5.2 × 12) / 22.5 = 2.77, which is in the insulin-resistant range.
How fast can it improve?+
Faster than most people expect. Studies on resistance training show 10–20% reductions in fasting insulin within 4–6 weeks of consistent training, even before significant body composition change. Caloric restriction and weight loss compound this.
This page describes biomarker research and reference ranges for self-tracking and research-context discussion only. It is not medical advice, not a diagnosis, and not a substitute for a qualified physician. Take any concerns about your health to a clinician.
Have your own panel? Read it next to the standard reference ranges with our free analyse tool.
Analyse my blood work →